volume 26, issue 6, P334-340 2018
DOI: 10.1007/s12471-018-1120-6
View full text
|
Sign up to set email alerts
|
Share

Abstract: Patients with atrial fibrillation who undergo a coronary intervention are eligible for both anticoagulation and (dual) antiplatelet therapy ((D)APT). An optimal balance has to be found to reduce the thromboembolic risk (i.e. stroke, systemic embolism and myocardial infarction) and to minimise the increased risk of bleeding with concomitant use of an anticoagulant and (D)APT. Owing to a lack of evidence, the guideline recommendations are predominantly based on expert opinion. Current evidence indicates that the…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

1
3
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals